MetaVia

MetaVia P/TBV

The Price to Tangible Book Value (P/TBV) of MetaVia (MTVA) as of Oct 30, 2026 is 1.02. In the previous year, Price to Tangible Book Value (P/TBV) was 0.69 — a change of 48.72% (higher).

P/TBV

1.02

YoY

48.72%

Last updated:

Price to Tangible Book Value (P/TBV) of MetaVia is 2025 1.02 . Price to Tangible Book Value (P/TBV) of MetaVia was 2024 0.69 . It decreases by 48.72% higher compared to the previous year.

The MetaVia P/TBV history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/TBV
Date
P/TBV
Jan 1, 2018
-0.41 USD
Jan 1, 2019
0.44 USD
Jan 1, 2020
0.75 USD
Jan 1, 2021
0.37 USD
Jan 1, 2022
0.25 USD
Jan 1, 2023
0.33 USD
Jan 1, 2024
0.69 USD
Jan 1, 2025
1.02 USD
The MetaVia P/TBV history
YEARP/TBVYoY
1.02+48.72%
0.69+110.38%
0.33+30.36%
0.25-32.89%
0.37-50.65%
0.75+70.65%
0.44-208.09%
-0.41-129.66%
1.38+423.52%
0.26-160.00%
-0.44-95.71%
-10.24—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MetaVia Stock analysis

What does MetaVia do? NeuroBo Pharmaceuticals, Inc. generates revenue by developing novel pharmaceuticals to address unmet medical needs in patients suffering from neurodegenerative disorders. The company focuses on specific therapeutic areas including Painful Diabetic Neuropathy (PDN) and Alzheimer’s disease, targeting these conditions with its proprietary product candidates. This strategy allows the firm to serve the clinical-stage biotechnology market by offering specialized treatments for serious health conditions. The company’s product portfolio includes NB-01, which is designed to target neuropathic pain with an indication for PDN, and NB-02, a drug developed for Alzheimer’s and tauopathies. Additionally, the firm offers Gemcabene, a therapy focused on treating dyslipidemia, a condition that increases the risk of life-threatening cardiovascular disease. Gemcabene is specifically directed at orphan indications such as homozygous familial hypercholesterolemia (HoFH) and severe hypertriglyceridemia (SHTG). Furthermore, NeuroBo Pharmaceuticals, Inc. is developing a capsule formulation of niclosamide for coronavirus indications. By expanding its research into these diverse medical conditions, the company aims to provide comprehensive pharmaceutical solutions. The firm operates from its headquarters in Boston, Massachusetts, and maintains a focused development pipeline to bring these treatments to market. MetaVia is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MetaVia stock

Price to Tangible Book Value (P/TBV) of MetaVia is 1.02 in 2025.

Price to Tangible Book Value (P/TBV) of MetaVia changed from 0.69 to 1.02, representing a 48.72% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Price to Tangible Book Value (P/TBV) MetaVia since 2006 – with annual values, charts, and detailed analysis.

P/TBV compares the stock price to tangible book value per share, excluding goodwill and intangibles. It provides a conservative asset-based valuation.

To evaluate Price to Tangible Book Value (P/TBV)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Price to Tangible Book Value (P/TBV).

A 'good' varies by industry and company stage. On Eulerpool, you can compare Price to Tangible Book Value (P/TBV)'s MetaVia with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — MetaVia

All Key Metrics — MetaVia